Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open-label Study to Evaluate Safety and Tolerability, and to Explore the Efficacy, of Dosing Regimens of Intraarticular 4975 in Patients With Chronic Moderate to Severe Pain of the Knee Associated With Osteoarthritis

Next Previous
Trial Profile

A Phase 2, Open-label Study to Evaluate Safety and Tolerability, and to Explore the Efficacy, of Dosing Regimens of Intraarticular 4975 in Patients With Chronic Moderate to Severe Pain of the Knee Associated With Osteoarthritis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capsaicin (Primary)
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Adverse reactions
  • Sponsors Anesiva

Most Recent Events

  • 26 Sep 2017 According to a Centrexion Therapeutics media release, data will be presented at the 11th Annual Pain and Migraine Therapeutics Summit 2017.
  • 06 May 2009 Actual end date changed from Dec 2008 to Jun 2008 as reported by ClinicalTrials.gov.
  • 03 Mar 2009 Actual number of patients (54) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top